Polymorphisms of peroxisome proliferator-activated receptors and survival of lung cancer and upper aero-digestive tract cancers

Lung Cancer

Volumn 85, Issue 3, 2014, Pages 449-456

  Yang, Ying ^a   Burke, Rita V ^b,c   Jeon, Christie Y ^d   Chang, Shen Chih ^a   Chang, Po Yin ^a,e,f   Morgenstern, Hal ^g   Tashkin, Donald P ^h   Mao, Jenny ⁱ   Cozen, Wendy ^c   Mack, Thomas M ^c   Rao, Jianyu ^a,h   Zhang, Zuo Feng ^a,h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^g UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

Author keywords

Lung cancer; Peroxisome proliferator activated receptors; Single nucleotide polymorphism; Survival; Upper aero digestive tract cancers

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; DIGESTIVE SYSTEM CANCER; FEMALE; GENETIC ASSOCIATION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HOMOZYGOTE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UPPER AERO DIGESTIVE TRACT CANCER; AGED; ALLELE; CANCER GRADING; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; HEAD AND NECK NEOPLASMS; LUNG NEOPLASMS; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; AGED; ALLELES; FEMALE; FOLLOW-UP STUDIES; GENE-ENVIRONMENT INTERACTION; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84926407434     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.06.014     Document Type: Article

References (61)

1. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2013, International Agency for Research on Cancer, Lyon, France, Available from: http://globocan.iarc.fr (accessed 29.01.14).
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
3. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer. National Cancer Institute. Bethesda, MD, . http://seer.cancer.gov/statfacts/html/lungb.html.
4. Reka A.K., Goswami M.T., Krishnapuram R., Standiford T.J., Keshamouni V.G. Molecular cross-regulation between PPAR-gamma and other signaling pathways: implications for lung cancer therapy. Lung Cancer 2011, 72(2):154-159.
5. Edge S.B., Compton C.C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17(6):1471-1474.
6. Kota B.P., Huang T.H., Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharmacol Res 2005, 51(2):85-94.
7. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. ChemInform 2000, 31(22).
8. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., et al. The nuclear receptor superfamily: the second decade. Cell 1995, 83(6):835.
9. Luquet S., Gaudel C., Holst D., Lopez-Soriano J., Jehl-Pietri C., Fredenrich A., et al. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim Biophys Acta (BBA): Mol Basis Dis 2005, 1740(2):313-317.
10. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995, 270(22):12953-12956.
11. Misra P., Owuor E.D., Li W., Yu S., Qi C., Meyer K., et al. Phosphorylation of transcriptional coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP). J Biol Chem 2002, 277(50):48745-48754.
12. Chang T.H., Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res 2000, 60(4):1129-1138.
13. Sasaki H., Tanahashi M., Yukiue H., Moiriyama S., Kobayashi Y., Nakashima Y., et al. Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer 2002, 36(1):71-76.
14. Spagnolo A., Glick R.P., Lin H., Cohen E.P., Feinstein D.L., Lichtor T. Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-γ thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts. J Neurosurg 2007, 106(2):299-305.
15. He T.-C., Chan T.A., Vogelstein B., Kinzler K.W. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999, 99(3):335-345.
16. Barak Y., Liao D., He W., Ong E.S., Nelson M.C., Olefsky J.M., et al. Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A 2002, 99(1):303-308.
17. Harman F.S., Nicol C.J., Marin H.E., Ward J.M., Gonzalez F.J., Peters J.M. Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nat Med 2004, 10(5):481-483.
18. Keshamouni V.G., Han S., Roman J. Peroxisome proliferator-activated receptors in lung cancer. PPAR Res 2007, 2007:90289.
19. Hashibe M., Morgenstern H., Cui Y., Tashkin D.P., Zhang Z.-F., Cozen W., et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2006, 15(10):1829-1834.
20. Cao W., Hashibe M., Rao J.Y., Morgenstern H., Zhang Z.F. Comparison of methods for DNA extraction from paraffin-embedded tissues and buccal cells. Cancer Detect Prev 2003, 27(5):397-404.
21. Greenland S. Bayesian perspectives for epidemiological research. II. Regression analysis. Int J Epidemiol 2007, 36(1):195-202.
22. Sullivan S.G., Greenland S. Bayesian regression in SAS software. Int J Epidemiol 2013, 42(1):308-317.
23. Chen D., Jin G., Wang Y., Wang H., Liu H., Liu Y., et al. Genetic variants in peroxisome proliferator-activated receptor-gamma gene are associated with risk of lung cancer in a Chinese population. Carcinogenesis 2008, 29(2):342-350.
24. Sundvold H., Brzozowska A., Lien S. Characterisation of bovine peroxisome proliferator-activated receptors γ1 and γ2: genetic mapping and differential expression of the two isoforms. Biochem Biophys Res Commun 1997, 239(3):857-861.
25. Deeb S.S., Fajas L., Nemoto M., Pihlajamäki J., Mykkänen L., Kuusisto J., et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20(3):284-287.
26. Fajas L., Auboeuf D., Raspé E., Schoonjans K., Lefebvre A.-M., Saladin R., et al. The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 1997, 272(30):18779-18789.
27. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. dbSNP accession:{rs1801282}, (dbSNP Build ID: {89/138}). Available from: . http://www.ncbi.nlm.nih.gov/SNP/.
28. Theocharis S., Kanelli H., Politi E., Margeli A., Karkandaris C., Philippides T., et al. Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer 2002, 36(3):249-255.
29. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. dbSNP accession:{rs3734254}, (dbSNP Build ID: {107/138}). Available from: . http://www.ncbi.nlm.nih.gov/SNP/.
30. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. dbSNP accession:{rs2076167}, (dbSNP Build ID: {96/138}). Available from: . http://www.ncbi.nlm.nih.gov/SNP/.
31. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. dbSNP accession:{rs1053049}, (dbSNP Build ID: {86/138}). Available from: . http://www.ncbi.nlm.nih.gov/SNP/.
32. Hunt R., Sauna Z.E., Ambudkar S.V., Gottesman M.M., Kimchi-Sarfaty C. Silent (synonymous) SNPs: should we care about them?. Single nucleotide polymorphisms 2009, 23-39. Springer.
33. Wagner K.D., Wagner N. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther 2010, 125(3):423-435.
34. Braissant O., Foufelle F., Scotto C., Dauça M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137(1):354-366.
35. Müller-Brüsselbach S., Kömhoff M., Rieck M., Meissner W., Kaddatz K., Adamkiewicz J., et al. Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ-deficient mice. EMBO J 2007, 26(15):3686-3698.
36. Muller-Brusselbach S., Ebrahimsade S., Jakel J., Eckhardt J., Rapp U., Peters J.M., et al. Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARss/delta gene. Int J Oncol 2007, 31(3):607.
37. Pedchenko T.V., Gonzalez A.L., Wang D., DuBois R.N., Massion P.P. Peroxisome proliferator-activated receptor β/δ expression and activation in lung cancer. Am J Respir Cell Mol Biol 2008, 39(6):689.
38. Han S., Ritzenthaler J.D., Wingerd B., Roman J. Activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein β. J Biol Chem 2005, 280(39):33240-33249.
39. Han S., Ritzenthaler J.D., Zheng Y., Roman J. PPARβ/δ agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-κB signals. Am J Physiol Lung Cell Mol Physiol 2008, 294(6):L1238-L1249.
40. Tan N.S., Icre G., Montagner A., Bordier-ten Heggeler B., Wahli W., Michalik L. The nuclear hormone receptor peroxisome proliferator-activated receptor β/δ potentiates cell chemotactism, polarization, and migration. Mol Cell Biol 2007, 27(20):7161-7175.
41. Meissner M., Hrgovic I., Doll M., Kaufmann R. PPARdelta agonists suppress angiogenesis in a VEGFR2-dependent manner. Arch Dermatol Res 2011, 303(1):41-47.
42. Piqueras L., Reynolds A.R., Hodivala-Dilke K.M., Alfranca A., Redondo J.M., Hatae T., et al. Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 2007, 27(1):63-69.
43. Shirotani M., Yui Y., Hattori R., Kawai C. U-61, 431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins 1991, 41(2):97-110.
44. Michalik L., Desvergne B., Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004, 4(1):61-70.
45. Tachibana K., Yamasaki D., Ishimoto K. The role of PPARs in cancer. PPAR Res 2008, 2008.
46. Shi Y., Hon M., Evans R.M. The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci U S A 2002, 99(5):2613-2618.
47. Peters J.M., Hollingshead H.E., Gonzalez F.J. Role of peroxisome-proliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin Sci (Lond, Engl: 1979) 2008, 115(4):107.
48. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357(9255):539-545.
49. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5(10):749-759.
50. Scott H., McMillan D, Forrest L., Brown D., McArdle C., Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002, 87(3):264-267.
51. Forrest L.M., McMillan D.C., McArdle C.S., Angerson W.J., Dagg K., Scott H.R. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005, 92(10):1834-1836.
52. Lee J.M., Yanagawa J., Peebles K.A., Sharma S., Mao J.T., Dubinett S.M. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 2008, 66(3):208.
53. Mann J.R., Backlund M.G., DuBois R.N. Mechanisms of disease: inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2005, 2(4):202-210.
54. Ulrich C.M., Bigler J., Potter J.D. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006, 6(2):130-140.
55. Wu C.W., Yu J., Sung J. Peroxisome proliferator-activated receptor delta and gastric cancer (Review). Oncol Rep 2009, 22(3):451.
56. Fucci A., Colangelo T., Votino C., Pancione M., Sabatino L., Colantuoni V. The role of peroxisome proliferator-activated receptors in the esophageal, gastric, and colorectal cancer. PPAR Res 2012, 2012:242498.
57. Peters J.M., Gonzalez F.J. Sorting out the functional role (s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer. Biochim Biophys Acta (BBA): Rev Cancer 2009, 1796(2):230-241.
58. Bishop-Bailey D., Swales K.E. The role of PPARs in the endothelium: implications for cancer therapy. PPAR Res 2008, 2008.
59. Müller R., Rieck M., Müller-Brüsselbach S. Regulation of cell proliferation and differentiation by PPAR. PPAR Res 2008, 2008.
60. Barish G.D., Narkar V.A., Evans R.M. PPARdelta: a dagger in the heart of the metabolic syndrome. J Clin Investig 2006, 116(3):590.
61. Peters J.M., Shah Y.M., Gonzalez F.J. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012, 12(3):181-195.